论文部分内容阅读
目的:观测普米克令舒联合可必特(复方异丙托溴胺)雾化吸入治疗中、重度哮喘急性发作的临床疗效。方法:选择50例中、重度支气管哮喘急性发作的患者,随机分为试验组和对照组。试验组25例,在常规治疗基础上给予普米克令舒联合可必特雾化吸入;对照组25例,采用常规综合疗法,观察2组症状,体征消失天数及临床疗效。结果:治疗组总有效率96%,高于对照组88%,差异有统计学意义(P<0.05),且治疗组症状,体征消失天数少于对照组,差异有统计学意义(P<0.05)。结论:普米克令舒联合可必特雾化吸入能迅速缓解中重度哮喘的急性发作,疗效优于常规综合治疗。
Objective: To observe the clinical efficacy of pulmicort and shunt combined with benezole (compound ipratropium bromide) atomization inhalation in the treatment of acute exacerbation of moderate and severe asthma. Methods: Fifty patients with moderate or severe bronchial asthma were randomly divided into test group and control group. In the experimental group, 25 cases were treated with Pulmicort respules combined with Kebian nebulized inhalation on the basis of routine treatment. In the control group, 25 cases were treated with conventional combination therapy. The symptoms, disappearance days and clinical curative effect of the two groups were observed. Results: The total effective rate of the treatment group was 96%, which was higher than that of the control group (88%), the difference was statistically significant (P <0.05), and the number of symptoms and signs disappeared in the treatment group was less than that in the control group ). Conclusion: Pulmicort respules combined with Kebite nebulization can quickly relieve acute exacerbation of moderate-severe asthma, and its curative effect is better than that of conventional combined therapy.